

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Lara E. Sucheston-Campbell¹, Rikki Cannioto², Alyssa I. Clay³, John Lewis Etter², Kevin H. Eng⁴, Song Liu⁴, Sebastiano Battaglia⁵, Qiang Hu⁴, J. Brian Szender⁶, Albina Minlikeeva², Janine M. Joseph², Paul Mayor⁶, Scott I. Abrams⁷, Brahm H. Segal^{7,8}, Paul K. Wallace⁹, Kah Teong Soh⁹, Emese Zsiros⁶, Hoda Anton-Culver¹⁰, Elisa V. Bandera¹¹, Matthias W. Beckmann¹², Andrew Berchuck¹³, Line Borge^{14,15}, Amanda Bruegl¹⁶, Ian G. Campbell^{17,18}, Shawn Patrice Campbell¹⁶; Georgia Chenevix-Trench¹⁹, on behalf of the Australian Ovarian Cancer Study; Daniel W. Cramer^{20,21}, Agnieszka Dansonka-Mieszkowska²², Fanny Dao²³, Brenda Diergaarde²⁴, Thilo Doerk²⁵, Jennifer A. Doherty²⁶, Andreas du Bois^{27,28}, Diana Eccles^{29,30}, Svend Aage Engelholm³¹, Peter A. Fasching¹², Simon A. Gayther^{32,33}, Aleksandra Gentry-Maharaj³⁴, Rosalind M. Glasspool³⁵, Marc T. Goodman^{36,37}, Jacek Gronwald³⁸, Philipp Harter²⁷, Alexander Hein¹², Florian Heitz^{27,28}, Peter Hillemanns²⁵, Claus Høgdall³⁹, Estrid V.S. Høgdall^{40,41}, Tomasz Huzarski³⁸, Allan Jensen⁴⁰, Sharon E. Johnatty¹⁹, Audrey Jung^{42,43}, Beth Y. Karlan⁴⁴, Reudiger Klapdor²⁵, Tomasz Kluz⁴⁵, Bożena Konopka²², Susanne Krüger Kjær^{39,40}, Jolanta Kupryjanczyk²², Diether Lambrechts⁴⁶, Jenny Lester⁴⁴, Jan Lubiński³⁸, Douglas A. Levine²³, Lene Lundvall⁴⁷, Valerie McGuire⁴⁸, Iain A. McNeish⁴⁹, Usha Menon³⁴, Francesmary Modugno^{24,50,51}, Roberta B. Ness⁵², Sandra Orsulic⁴⁴, James Paul³⁵, Celeste Leigh Pearce^{53,54}, Tanja Pejovic^{16,55}, Paul Pharoah^{56,57}, Susan J. Ramus^{58,59}, Joseph Rothstein⁴⁸, Mary Anne Rossing^{60,61}, Matthias Rübner¹², Joellen M. Schildkraut⁶², Barbara Schmalfeldt⁶³, Ira Schwaab⁶⁴, Nadeem Siddiqui⁶⁵, Weiva Sieh^{66,67}, Piotr Sobiczewski⁶⁸, Honglin Song⁵⁶, Kathryn L. Terry^{20,21}, Els Van Nieuwenhuysen⁶⁹, Adriaan Vanderstichele⁶⁹, Ignace Vergote⁶⁹, Christine S. Walsh⁴⁴, Penelope M. Webb⁷⁰, Nicolas Wentzensen⁷¹, Alice S. Whittemore⁴⁸, Anna H. Wu⁵⁴, Argyrios Ziogas⁷², Kunle Odunsi⁶, Jenny Chang-Claude^{42,43}, Ellen L. Goode⁷³, and Kirsten B. Moysich²

Abstract

Background: The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/promutagenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses.

Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive EOC. Versatile Gene-based Association Study and the admixture likelihood

method were used to test gene and pathway associations with survival.

Results: We did not identify individual SNPs that were significantly associated with survival after correction for multiple testing ($P < 3.5 \times 10^{-5}$), nor did we identify significant associations between the MDSC pathway overall, or the 24 individual genes and EOC survival.

Conclusions: In this well-powered analysis, we observed no evidence that inherited variations in MDSC-associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes.

Impact: Common inherited variation in genes relevant to MDSCs was not associated with survival in women diagnosed with invasive EOC. *Cancer Epidemiol Biomarkers Prev*; 26(3): 1–5. ©2016 AACR.

¹College of Pharmacy, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio. ²Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York. ³Cancer Genetic Epidemiology, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota. ⁴Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York. ⁵Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York. ⁶Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York. ⁷Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York.

⁸Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York. ⁹Department of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York. ¹⁰Genetic Epidemiology Research Institute, School of Medicine, University of California Irvine, Irvine, California. ¹¹Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. ¹²Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. ¹³Department of Obstetrics and

Introduction

Survival after a diagnosis of epithelial ovarian cancer (EOC) has seen only modest improvements in recent decades, making the identification of novel mechanisms and pathways associated with EOC prognosis imperative. EOC is associated with immunosuppressive pathways, including regulatory T cells and myeloid-derived suppressor cells (MDSC) that can be barriers to antitumor immunity and adversely affect clinical outcomes. To this end, MDSCs suppress the antigen-specific T-cell response by both CD4⁺ and CD8⁺ T cells, and elevated concentrations of MDSCs have been detected in the peripheral blood of cancer patients when compared with normal controls (1, 2). We hypothesized that common inherited genetic variation in genes involved in the MDSC pathway is associated with survival following ovarian cancer diagnosis.

Materials and Methods

We conducted a pooled analysis utilizing individual-level data from 28 studies in the Ovarian Cancer Association Consortium to assess the association of genes in the MDSC-associated pathway with EOC survival. Participants included 11,034 women ages 18 years and older with a histologically confirmed primary diagnosis of invasive EOC, fallopian tube cancer, or primary peritoneal cancer who were genotyped on the Illumina iSelect array designed for the Collaborative Oncological Gene-environment Study (3). Clinical, epidemiologic, and follow-up data were made available for all analyses.

To assess the association between invasive EOC outcome and inherited variation in the MDSC pathway, we conducted SNP, gene, and pathway-based analyses of 24 candidate genes relevant to the biology of MDSCs, as established from an extensive literature review utilizing the PubMed database (*ARG1*, *CD274*,

Gynecology, Duke University Medical Center, Durham, North Carolina.¹⁴Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway.¹⁵Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.¹⁶Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.¹⁷Cancer Genetics Laboratory, East Melbourne, Australia.¹⁸Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.¹⁹Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, Australia.²⁰Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.²¹Harvard T. H. Chan School of Public Health, Boston, Massachusetts.²²Department of Pathology and Laboratory Diagnostics, the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.²³Gynecologic Oncology, Laura and Isaac Pearlmuter Cancer Center, NYU Langone Medical Center, New York, New York.²⁴Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.²⁵Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany.²⁶Department of Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.²⁷Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huysens-Stiftung/Knappschaft GmbH, Essen, Germany.²⁸Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.²⁹Faculty of Medicine, University of Southampton, Southampton, United Kingdom.³⁰Wessex Clinical Genetics Service, Southampton University Hospitals Trust, Southampton, United Kingdom.³¹Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.³²Center for Cancer Prevention and Translational Genomics, Cedars-Sinai Medical Center, Los Angeles, California.³³Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.³⁴Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom.³⁵The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.³⁶Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.³⁷Department of Biomedical Sciences, Community and Population Health Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.³⁸Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.³⁹Department of Gynaecology, Rigshospitalet, University of Copenhagen, Herlev, Denmark.⁴⁰Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.⁴¹Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.⁴²Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.⁴³University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Heidelberg, Germany.⁴⁴Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.⁴⁵Clinic of Obstetrics and Gynecology, Institute of Midwifery and Emergency Medicine, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland.⁴⁶Department of Oncology, Laboratory for Translational Genetics, Vesalius Research Center, University of Leuven, Leuven, Belgium.⁴⁷Department of Gynecology, The Juliane Marie Centre, Rigshospitalet, Univer-

sity of Copenhagen, Copenhagen, Denmark.⁴⁸Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.⁴⁹Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, United Kingdom.⁵⁰Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.⁵¹Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.⁵²The University of Texas School of Public Health, Houston, Texas.⁵³Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.⁵⁴Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.⁵⁵Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.⁵⁶Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.⁵⁷Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.⁵⁸School of Women's and Children's Health, University of New South Wales, New South Wales, Australia.⁵⁹The Kinghorn Cancer Centre, Garvan Institute of Medical Research, New South Wales, New South Wales, Australia.⁶⁰Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.⁶¹Department of Epidemiology, University of Washington, Seattle, Washington.⁶²Department of Public Health Sciences, The University of Virginia, Charlottesville, Virginia.⁶³Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.⁶⁴Praxis für Humangenetik, Wiesbaden, Germany.⁶⁵Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom.⁶⁶Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.⁶⁷Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.⁶⁸Department of Gynecologic Oncology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.⁶⁹Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.⁷⁰Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Australia.⁷¹Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.⁷²Department of Epidemiology, University of California Irvine, Irvine, California.⁷³Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.

L.E. Sucheston-Campbell and R. Cannioto are first co-authors of this article.

Corresponding Author: Kirsten B. Moysich, Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-8004; Fax: 716-845-8125; E-mail: kirsten.moysich@roswellpark.org

doi: 10.1158/1055-9965.EPI-16-0631

©2016 American Association for Cancer Research.

Table 1. Clinical characteristics of invasive EOC cases from the Ovarian Cancer Association Consortium analyzed for association with MDSC genetic variation

Patient characteristics	Vital status at last follow-up		Total invasive EOC cases N = 10,751
	Alive n = 5,243 (48.8%)	Deceased n = 5,508 (51.2%)	
Age at diagnosis			
<50 years	1,627 (59.1%)	1,125 (40.9%)	2,752
50–69 years	3,100 (47.4%)	3,445 (52.6%)	6,545
70+ years	516 (35.5%)	938 (64.5%)	1,454
Histology			
Serous	2,765 (39.7%)	4,207 (60.3%)	6,972
High-grade serous	2,210 (38.2%)	3,568 (61.8%)	5,578
Mucinous	504 (72.1%)	197 (27.9%)	701
Endometrioid	1,058 (68.7%)	485 (31.3%)	1,543
Clear cell	529 (67.1%)	260 (32.9%)	789
Mixed cell	215 (56.7%)	166 (43.3%)	381
Undifferentiated/poorly differentiated	92 (42.6%)	124 (57.4%)	216
Unknown epithelial	70 (49.6%)	69 (50.3%)	139
Grade			
Well differentiated	757 (70.5%)	316 (29.3%)	1,073
Moderately differentiated	1,107 (50.6%)	1,079 (49.4%)	2,186
Poorly differentiated	2,185 (42.4%)	2,969 (57.6%)	5,154
Undifferentiated	284 (46.8%)	323 (53.2%)	607
Unknown	583 (58.1%)	419 (41.9%)	1,002
Stage			
Localized	1,393 (81.3%)	320 (18.7%)	1,713
Regional	1,314 (66.4%)	665 (33.6%)	1,979
Distant	2,109 (34.3%)	4,034 (65.7%)	6,134
Unknown	178 (55.5%)	143 (44.5%)	321

CSF2, *CSF3*, *EIF2AK4*, *FLT3*, *IL10RA*, *IL13RA2*, *IL4*, *IL4R*, *IL5RA*, *IL6R*, *IDO*, *IRF8*, *KITLG*, *MMP1*, *MMP12*, *MMP3*, *MMP9*, *NOS2A*, *PSME4*, *STAT1*, *STAT3*, and *VEGFA*). SNP selection and quality control were performed as described previously, yielding a total of 736 SNPs for analyses (4). We calculated the effective number of independent SNPs tested; this value was used in a Bonferroni correction to determine single-SNP significance (4). We utilized Cox proportional hazards regression models adjusted for age, tumor stage, and grade to estimate HRs and 95% confidence intervals (CI) representing SNP associations with EOC overall and by invasive histotype. Survival time was defined as the time from diagnosis of invasive EOC until death from any cause or time of last follow-up. Analyses accommodated left truncation to account for prevalent cases where appropriate and right censoring was done at >10 years follow-up time. Analyses and graphics were done using R (<https://www.r-project.org>). Gene- and pathway-based tests of association with hazard of death were performed using Versatile Gene-based Association Study and the admixture likelihood method, respectively (5, 6).

Results

The clinical characteristics of the study population are presented in Table 1. As expected, the majority of patients were diagnosed with serous EOCs, had poorly differentiated tumors, and were diagnosed with distant disease.

We considered $P < 3.5 \times 10^{-5}$ as the threshold for significance, based on a Bonferroni correction for the estimated number of independent SNPs ($n = 288$) across five histotypes. Single SNP associations for EOC overall and by invasive histotype are shown in circular Manhattan style plots in Fig. 1 with SNPs showing $P < 0.01$ highlighted in red. The most significant single SNP was the C allele of rs6492925 in *EIF2AK4* on chromosome 15, with a reduction in hazard of death in

women with mucinous tumors (HR = 0.57; 95% CI, 0.42–0.78; $P = 3.7 \times 10^{-4}$).

The most significant gene-based associations for all invasive ovarian cancer cases (*KITLG*, $P = 0.07$), high-grade serous (*VEGFA*, $P = 0.11$), mucinous (*EIF2AK4*, $P = 0.015$), endometrioid (*CSF*, $P = 0.02$), and clear cell (*CD274*, $P = 0.037$) did not pass multiple test correction threshold set for testing the 24 genes. Taken together, the 24 genes showed no significant association with any histotype; mucinous cell tumors showed the most significant MDSC pathway association with survival ($P = 0.11$).

Discussion

Assuming genotyping captures, on average, 70% of the variation in each gene for tests of association with overall EOC and given the proportion of events at 51%, our study had 80% power at $P < 3.5 \times 10^{-5}$ to detect an HR of 1.11 to 1.24 for minor allele frequencies between 40% and 10%, respectively. We conducted a well-powered, hypothesis-driven study to evaluate a role for common inherited variation in MDSC pathway genes with EOC survival; we observed no evidence of an association at the SNP, gene or pathway level with EOC survival. To date, neither genome wide analyses of single SNP association with progression-free survival nor copy number variation with overall survival showed significant findings and did not report suggestive associations in these genes (7, 8). It is possible that rare variation in MDSC-associated genes not captured by these analyses could be correlated with EOC outcomes or that the magnitude of effect sizes was below detection. In addition, recent work has identified an expanding list of genes associated with MDSCs; thus, future studies should consider the importance of this emerging knowledge of MDSC biology.




Figure 1.

These five concentric circles are circular standard Manhattan plots. The chromosome is on the outer circle, $-\log_{10} P$ values are on the y-axis (vertical), with each circle representing the P value from single SNP tests of association with overall survival adjusted for age, stage, and grade. **A-E**, The Manhattan plots are as follows: all ovarian cancer cases (**A**); high-grade serous (**B**); mucinous cell (**C**); endometrioid (**D**); and clear cell (**E**). The red dashed line designates $P = 0.01$, $-\log_{10}(P \text{ value}) = 2$, with all red-colored SNPs above that line reflecting SNPs $P < 0.01$.

Disclosure of Potential Conflicts of Interest

P.A. Fasching reports receiving commercial research grants from Amgen and Novartis and has received speakers bureau honoraria from Novartis and Pfizer. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: L.E. Sucheston-Campbell, E. Zsiros, H. Anton-Culver, M.W. Beckmann, S.A. Engelholm, A. Ziogas, E.L. Goode, K.B. Moysich
Development of methodology: L.E. Sucheston-Campbell, P. Mayor, P.K. Wallace, S.A. Engelholm, T. Huzarski, K.B. Moysich
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Mayor, P.K. Wallace, K.T. Soh, E. Zsiros, H. Anton-Culver, E.V. Bandera, M.W. Beckmann, A. Berchuck, L. Bjorge, I.G. Campbell, G. Chenevix-Trench, D.W. Cramer, A. Dansonka-Mieszkowska, F. Dao, B. Diergaard, T. Doerk, A. du Bois, D. Eccles, S.A. Engelholm, P.A. Fasching, S.A. Gayther, A. Gentry-Maharaj, R.M. Glasspool, M.T. Goodman, J. Gronwald, P. Harter, A. Hein, F. Heitz, P. Hillemmanns, C. Høgdall, T. Huzarski, A. Jensen, B.Y. Karlan, R. Klapdor, T. Kluz, B. Konopka, S.K. Kjær, J. Kupryjanczyk, D. Lambrechts, J. Lester, D.A. Levine, V. McGuire, U. Menon,

F. Modugno, R.B. Ness, S. Orsulic, J. Paul, T. Pejovic, P. Pharoah, S.J. Ramus, M.A. Rossing, M. Rübner, J.M. Schildkraut, N. Siddiqui, P. Sobiczewski, H. Song, K.L. Terry, E. Van Nieuwenhuysen, A. Vanderstichele, I. Vergote, C.S. Walsh, P.M. Webb, N. Wentzensen, A.S. Whittemore, A.H. Wu, A. Ziogas, K. Odunsi, J. Chang-Claude, E.L. Goode, K.B. Moysich

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L.E. Sucheston-Campbell, A.I. Clay, J.L. Etter, K.H. Eng, S. Liu, S. Battaglia, Q. Hu, J.B. Szender, P. Mayor, S.I. Abrams, B.H. Segal, P.K. Wallace, D. Lambrechts, R.B. Ness, P. Pharoah, M.A. Rossing, B. Schmalfeldt, W. Sieh, I. Vergote, A. Ziogas, K. Odunsi, K.B. Moysich

Writing, review, and/or revision of the manuscript: L.E. Sucheston-Campbell, R. Cannioto, A.I. Clay, J.L. Etter, K.H. Eng, S. Battaglia, J.B. Szender, A. Minlikeeva, J.M. Joseph, P. Mayor, S.I. Abrams, B.H. Segal, P.K. Wallace, K.T. Soh, E. Zsiros, H. Anton-Culver, E.V. Bandera, M.W. Beckmann, A. Berchuck, L. Bjorge, A. Bruegl, G. Chenevix-Trench, D.W. Cramer, B. Diergaard, J.A. Doherty, A. du Bois, D. Eccles, P.A. Fasching, A. Gentry-Maharaj, R.M. Glasspool, M.T. Goodman, J. Gronwald, P. Harter, F. Heitz, P. Hillemmanns, C. Høgdall, E.V.S. Høgdall, A. Jensen, S.E. Johnatty, A. Jong, B.Y. Karlan, R. Klapdor, T. Kluz, B. Konopka, S.K. Kjær, D. Lambrechts, L. Lundvall, V. McGuire, I.A. McNeish, U. Menon, F. Modugno, R.B. Ness, C.L. Pearce, P. Pharoah, S.J. Ramus, M.A. Rossing, B. Schmalfeldt, N. Siddiqui,

W. Sieh, H. Song, I. Vergote, P.M. Webb, N. Wentzensen, A.H. Wu, K. Odunsi, J. Chang-Claude, E.L. Goode, K.B. Moysich

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.E. Sucheston-Campbell, R. Cannioto, J.L. Etter, J.M. Joseph, A. Berchuck, S.P. Campbell, G. Chenevix-Trench, A. Dansonka-Mieszkowska, T. Doerk, S.A. Engelholm, C. Høgdall, E.V.S. Høgdall, S.E. Johnatty, B.Y. Karlan, T. Kluz, D. Lambrechts, J. Lester, F. Modugno, S.J. Ramus, J. Rothstein, I. Schwaab

Study supervision: L.E. Sucheston-Campbell, S. Battaglia, P. Mayor, M.W. Beckmann, S.K. Kjær, F. Modugno, K.B. Moysich

Other (pathologist, clinical geneticist): J. Lubinski

Other (acquisition of clinical information): P. Sobiczewski

Grant Support

This work was supported by the following grants:

The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund.

This study used shared resources supported by RPCI's Cancer Center Support grant from the NCI (P30CA016056) and was also supported by the NCI Ovarian SPORE grant P50CA159981 and Roswell Park Alliance Foundation.

L.E. Sucheston-Campbell is supported by P50CA159981 and Roswell Park Alliance Foundation.

K.B. Moysich is supported by P50CA159981 and Roswell Park Alliance Foundation, NIH/NCIR01CA095023, and NIH/NCIR01CA126841.

K.H. Eng was supported by the Roswell Park Alliance Foundation.

S.I. Abrams was supported by R01CA140622.

B.H. Segal was supported by R01CA188900.

P.K. Wallace and this work was supported by Roswell Park Cancer Institute Ovarian Spore (1P50CA159981-01A1).

J.B. Szender was supported by 5T32CA108456.

Albina Minlikeeva was supported by Interdisciplinary Training Grant in Cancer Epidemiology (R25CA113951).

AUS (C. Chenevix-Trench and P.M. Webb): U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia, and Tasmania and Cancer Foundation of Western Australia (under Multi-State Applications 191, 211, and 182).

BAV (P.A. Fasching): ELAN Funds of the University of Erlangen-Nuremberg.

BEL (D. Lambrechts): Nationaal Kankerplan.

DOV (M.A. Rossing): NIH (R01-CA112523 and R01-CA87538).

GER (J. Chang-Claude): German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401), and the German Cancer Research Center (DKFZ).

HAW (M. Goodman): NIH (R01-CA58598, N01-CN-55424, and N01-PC-67001).

HOP (F. Modugno, K. Moysich, and R. Ness): DOD (DAMD17-02-1-0669) and NCI (K07-CA080668, R01-CA95023, and P50-CA159981); NIH/National Center for Research Resources/General Clinical Research Center grant MO1-RR000056; R01-CA126841.

LAX (B.Y. Karlan): American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000124.

MAL (S.K. Kjær): Funding for this study was provided by research grant R01-CA61107 from the NCI, research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark, and the Mermaid I project.

MAY (E.L. Goode): NIH (R01-CA122443, P30-CA15083, and P50-CA136393), Mayo Foundation, Minnesota Ovarian Cancer Alliance, and Fred C. and Katherine B. Andersen Foundation.

NCO (J. Schildkraut and A. Berchuck): NIH (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666).

NEC (D. Cramer and K. Terry): NIH (R01-CA54419 and P50-CA105009) and Department of Defense (W81XWH-10-1-02802).

NJO (E.V. Bandera): NCI (NIH-K07 CA095666, NIH-K22-CA138563, and P30-CA072720) and the Cancer Institute of New Jersey.

NOR (L. Bjorge): Helse Vest, The Norwegian Cancer Society, and The Research Council of Norway.

ORE (T. Pejovic): OHSU Foundation.

POC (J. Gronwald): Pomeranian Medical University.

POL (N. Wentzensen): Intramural Research Program of the NCI.

PVD (E. Høgdall and C. Høgdall): Herlev Hospitals Forskningsråd, Direktør Jacob Madsens og Hustru Olga Madsens fond, Arvid Nilssons fond, Gangsted fonden, Herlev Hospitals Forskningsråd, and Danish Cancer Society.

RMH (P. Pharoah): Cancer Research UK (no grant number is available) and Royal Marsden Hospital.

SEA (P. Pharoah): Cancer Research UK (C490/A10119 and C490/A10124) and UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge.

SRO (S. Banerjee, J. Paul, N. Siddiqui, R. Glasspool, and I. McNeish): Cancer Research UK (C536/A13086 and C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589).

STA (A.S. Whittemore and W. Sieh): NIH (U01-CA71966, R01-CA16056, K07-CA143047, and U01-CA69417) for recruitment of controls by the Cancer Prevention Institute of California.

UCI (H. Anton-Culver): NIH (R01-CA058860) and the Lon V Smith Foundation grant LVS-39420.

UKO (U Menon, A Gentry-Maharaj, and S. Gayther): The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

UKR (P. Pharoah): Cancer Research UK (C490/A6187) and UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge.

USC (C.L. Pearce): P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200).

WOC (J. Kupryjanczyk): National Science Centren (N N301 5645 40) The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 10, 2016; accepted August 26, 2016; published OnlineFirst September 27, 2016.

References

- Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. *Cancer Immunol Immunother* 2009;58:49–59.
- Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. *J Immunol* 2009;182:6562–8.
- Community Research and Development Information Service. Collaborative Oncological Gene-environment Study. Available from: http://cordis.europa.eu/project/rcn/92052_en.html.
- Hampras S, Sucheston-Campbell L, Cannioto R, Chang-Claude J, Modugno F, Dörk T, et al. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget* 2016;7:69097–110.
- Tyrer J, Pharoah PD, Easton DF. The admixture maximum likelihood test: a novel experiment-wise test of association between disease and multiple SNPs. *Genet Epidemiol* 2006;30:636–43.
- Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, et al. A versatile gene-based test for genome-wide association studies. *Am J Hum Genet* 2010;87:139–45.
- Fridley BL, Chalise P, Tsai YY, Sun Z, Vierkant RA, Larson MC, et al. Germline copy number variation and ovarian cancer survival. *Front Genet* 2012;3:142.
- French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, et al. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. *Oncotarget* 2016;7:6353–68.

Cancer Epidemiology, Biomarkers & Prevention

AACR American Association
for Cancer Research

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Lara E. Sucheston-Campbell, Rikki Cannioto, Alyssa I. Clay, et al.

Cancer Epidemiol Biomarkers Prev Published OnlineFirst September 27, 2016.

Updated version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-16-0631](https://doi.org/10.1158/1055-9965.EPI-16-0631)

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and
Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/early/2017/02/14/1055-9965.EPI-16-0631>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's
(CCC)
Rightslink site.